XORTX Therapeutics Inc (XRTX)

1.21
+0.07(+6.14%)
After Hours
1.29
+0.07(+5.74%)
- Real-time Data
  • Volume:
    36,192
  • Day's Range:
    1.15 - 1.28
  • 52 wk Range:
    0.90 - 5.89
Unusual Post-Market activity

Post-market activity occurs after regular market hours and can be used to judge market strength and direction. Post-market trading has some risk because of lower liquidity and more volatility than regular sessions.

XRTX Overview

Prev. Close
1.14
Day's Range
1.15-1.28
Revenue
-
Open
1.15
52 wk Range
0.9-5.89
EPS
-0.357
Volume
36,192
Market Cap
15.97M
Dividend (Yield)
0.30
(2.27%)
Average Vol. (3m)
503,654
P/E Ratio
-5.12
Beta
0.466
1-Year Change
-90.86%
Shares Outstanding
12,989,687
Next Earnings Date
Nov 28, 2022
What is your sentiment on XORTX Therapeutics?
or
Market is currently closed. Voting is open during market hours.

XORTX Therapeutics Inc News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

XORTX Therapeutics Inc Analysis

  • Futures Gain Into Fed Speak

    Futures Gain Into Fed Speak U.S. equity futures rose in early pre-market trade ahead of key speeches from FOMC voting members. New York Fed President William Dudley, who is a...

  • Futures Higher Ahead Of ECB, BOE

    Futures Higher Ahead of ECB, BOE U.S. equity futures rose modestly in early Thursday trade following strong Chinese trade data and ahead of the interest rate decisions of the...

XORTX Therapeutics Inc Company Profile

XORTX Therapeutics Inc Company Profile

Employees
0

XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is based in Vancouver, Canada.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesNeutralSellStrong BuySellStrong Sell
Technical IndicatorsSellSellStrong BuySellStrong Sell
SummaryNeutralSellStrong BuySellStrong Sell